PET-CT-guided characterisation of progressive, preclinical tuberculosis infection and its association with low-level circulating Mycobacterium tuberculosis DNA in household contacts in Leicester, UK: a prospective cohort study
- PMID: 38244554
- DOI: 10.1016/S2666-5247(23)00289-6
PET-CT-guided characterisation of progressive, preclinical tuberculosis infection and its association with low-level circulating Mycobacterium tuberculosis DNA in household contacts in Leicester, UK: a prospective cohort study
Abstract
Background: Incipient tuberculosis, a progressive state of Mycobacterium tuberculosis infection with an increased risk of developing into tuberculosis disease, remains poorly characterised. Animal models suggest an association of progressive infection with bacteraemia. Circulating M tuberculosis DNA has previously been detected in pulmonary tuberculosis by use of Actiphage, a bacteriophage-based real-time PCR assay. We aimed to investigate whether serial [18F]fluorodeoxyglucose ([18F]FDG)-PET-CT could be used to characterise the state and progressive trajectory of incipient tuberculosis, and examine whether these PET-CT findings are associated with Actiphage-based detection of circulating M tuberculosis DNA.
Methods: We did a prospective 12-month cohort study in healthy, asymptomatic adults (aged ≥16 years) who were household contacts of patients with pulmonary tuberculosis, and who had a clinical phenotype of latent tuberculosis infection, in Leicester, UK. Actiphage testing of participants' blood samples was done at baseline, and [18F]FDG PET-CT at baseline and after 3 months. Baseline PET-CT features were classified as positive, indeterminate, or negative, on the basis of the quantitation (maximum standardised uptake value [SUVmax]) and distribution of [18F]FDG uptake. Microbiological sampling was done at amenable sites of [18F]FDG uptake. Changes in [18F]FDG uptake after 3 months were quantitatively categorised as progressive, stable, or resolving. Participants received treatment if features of incipient tuberculosis, defined as microbiological detection of M tuberculosis or progressive PET-CT change, were identified.
Findings: 20 contacts were recruited between Aug 5 and Nov 5, 2020; 16 of these participants had a positive result on IFNγ release assay (QuantiFERON-TB Gold Plus [QFT]) indicating tuberculosis infection. Baseline PET-CT scans were positive in ten contacts (all QFT positive), indeterminate in six contacts (three QFT positive), and negative in four contacts (three QFT positive). Four of eight PET-CT-positive contacts sampled had M tuberculosis identified (three through culture, one through Xpert MTB/RIF Ultra test) from intrathoracic lymph nodes or bronchial wash and received full antituberculosis treatment. Two further unsampled PET-CT-positive contacts were also treated: one with [18F]FDG uptake in the lung (SUVmax 9·4) received empirical antituberculosis treatment and one who showed progressive [18F]FDG uptake received preventive treatment. The ten untreated contacts with [18F]FDG uptake at baseline (seven QFT positive) had stable or resolving changes at follow-up and remained free of tuberculosis disease after 12 months. A positive baseline Actiphage test was associated with the presence of features of incipient tuberculosis requiring treatment (p=0·018).
Interpretation: Microbiological and inflammatory features of incipient tuberculosis can be visualised on PET-CT and are associated with M tuberculosis detection in the blood, supporting the development of pathogen-directed blood biomarkers of tuberculosis risk.
Funding: MRC Confidence in Concept.
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests PH has received consultancy fees for two advisory board meetings with PBD Biotech since study inception. CR and BS hold stocks in PBD Biotech, the company commercialising the Actiphage technology. CR and BS have a pending patent on Actiphage bacteriophage-mediated mycobacterial DNA release assay testing (PCT/GB2020/050524). PBD Biotech supplied PCR reagents and components of the Actiphage kit for use in the study but had no role in design, execution, analysis, or reporting. All other authors declare no competing interests.
Similar articles
-
Multi-level tuberculosis of the spine identified by 18 F-FDG-PET/CT and concomitant urogenital tuberculosis: a case report from the spinal TB X cohort.Infection. 2024 Dec;52(6):2507-2519. doi: 10.1007/s15010-024-02327-5. Epub 2024 Jun 19. Infection. 2024. PMID: 38896371 Free PMC article.
-
Sequential 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scan findings in patients with extrapulmonary tuberculosis during the course of treatment-a prospective observational study.Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3118-3129. doi: 10.1007/s00259-020-04888-7. Epub 2020 Jun 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32483653
-
Interferon-gamma release assay conversion after Mycobacterium tuberculosis exposure specifically associates with greater risk of progression to tuberculosis: A prospective cohort study in Leicester, UK.Int J Infect Dis. 2024 Apr;141:106982. doi: 10.1016/j.ijid.2024.02.025. Epub 2024 Feb 24. Int J Infect Dis. 2024. PMID: 38408518
-
Towards more accurate 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging in active and latent tuberculosis.Int J Infect Dis. 2020 Mar;92S:S85-S90. doi: 10.1016/j.ijid.2020.02.017. Epub 2020 Feb 27. Int J Infect Dis. 2020. PMID: 32114199 Review.
-
CT and 18F-FDG PET abnormalities in contacts with recent tuberculosis infections but negative chest X-ray.Insights Imaging. 2022 Jul 7;13(1):112. doi: 10.1186/s13244-022-01255-y. Insights Imaging. 2022. PMID: 35796839 Free PMC article. Review.
Cited by
-
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.Pathog Immun. 2025 Mar 2;10(2):1-45. doi: 10.20411/pai.v10i2.791. eCollection 2025. Pathog Immun. 2025. PMID: 40062355 Free PMC article. Review.
-
A structural and metabolic framework for classifying pre-clinical tuberculosis infection phenotypes using 18F-FDG PET-CT: a prospective cohort analysis following M. tuberculosis exposure.Thorax. 2024 Nov 14;79(12):1156-1159. doi: 10.1136/thorax-2024-221470. Thorax. 2024. PMID: 38914470 Free PMC article.
-
The American Association of Tissue Banks tissue donor screening for Mycobacterium tuberculosis-Recommended criteria and literature review.Transpl Infect Dis. 2024 Nov;26 Suppl 1(Suppl 1):e14294. doi: 10.1111/tid.14294. Epub 2024 Jun 9. Transpl Infect Dis. 2024. PMID: 38852068 Free PMC article. Review.
-
Blood and urine early treatment response biomarkers in HIV-associated disseminated tuberculosis.South Afr J HIV Med. 2025 Apr 9;26(1):1664. doi: 10.4102/sajhivmed.v26i1.1664. eCollection 2025. South Afr J HIV Med. 2025. PMID: 40356939 Free PMC article.
-
Incipient tuberculosis: a comprehensive overview.Infection. 2024 Aug;52(4):1215-1222. doi: 10.1007/s15010-024-02239-4. Epub 2024 Apr 8. Infection. 2024. PMID: 38589748 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical